We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Within hours of the FDA authorizing booster doses of the Pfizer and Moderna COVID-19 vaccines for all adults, a Centers for Disease Control and Prevention (CDC) expert panel unanimously supported the decision. Read More
If approved, Paxlovid would be the first oral antiviral of its kind that could be prescribed as an at-home treatment to high-risk patients at the first sign of infection. Read More
Biogen’s Aduhelm (aducanumab) appears unlikely to receive a marketing authorization in the EU, after a European Medicines Agency expert panel issued a “negative trend” vote on the antiamyloid antibody. Read More
Pfizer has filed its application with the FDA for Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased risk of hospitalization or death. Read More